Insider Selling: Hims & Hers Health (NYSE:HIMS) CFO Sells $59,400.00 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 2,000 shares of the firm’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $29.70, for a total transaction of $59,400.00. Following the sale, the chief financial officer owned 234,527 shares of the company’s stock, valued at $6,965,451.90. This trade represents a 0.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Tuesday, September 22nd, Oluyemi Okupe sold 29,277 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.95, for a total transaction of $876,846.15.
• On Thursday, September 17th, Oluyemi Okupe sold 12,313 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.82, for a total transaction of $354,860.66.
• On Wednesday, August 19th, Oluyemi Okupe sold 4,938 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.99, for a total transaction of $148,090.62.
• On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.89, for a total transaction of $261,831.32.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.49, for a total value of $261,377.87.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $28.96 on Monday. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. The business has a fifty day simple moving average of $29.28 and a two-hundred day simple moving average of $28.27. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $65.30. The company has a market capitalization of $6.76 billion, a P/E ratio of -45.97 and a beta of 2.44.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The firm had revenue of $753.21 million during the quarter, compared to the consensus estimate of $698.90 million. During the same quarter in the previous year, the firm earned $0.17 earnings per share. The business’s quarterly revenue was up 38.2% compared to the same quarter last year. On average, analysts expect that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current year.

Institutional Trading of Hims & Hers Health

A number of large investors have recently modified their holdings of HIMS. Bank of America Corp DE lifted its position in Hims & Hers Health by 194.4% during the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock valued at $90,465,000 after purchasing an additional 2,877,550 shares during the last quarter. Norges Bank bought a new position in shares of Hims & Hers Health in the 4th quarter worth $62,153,000. Bank of New York Mellon Corp bought a new position in shares of Hims & Hers Health in the 2nd quarter worth $46,220,000. Bienville Capital Management LLC purchased a new stake in shares of Hims & Hers Health during the 2nd quarter valued at $27,242,000. Finally, Principal Financial Group Inc. lifted its holdings in shares of Hims & Hers Health by 97.3% during the 1st quarter. Principal Financial Group Inc. now owns 1,282,266 shares of the company’s stock worth $26,620,000 after acquiring an additional 632,282 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers and Hims Australia announced new management appointments, including chief medical officers for the UK and Australia. The moves could strengthen local clinical oversight and support the company’s international expansion strategy. Hims & Hers Names Chief Medical Officers in the UK and Australia
• Neutral Sentiment: Two insiders sold a combined 5,461 shares for approximately $160,357. Soleil Boughton sold 3,461 shares at an average of $29.17, while CFO Oluyemi Okupe sold 2,000 shares at $29.70. Both transactions were executed under pre-arranged Rule 10b5-1 plans, and each insider retained substantial holdings, reducing the significance of the sales as a standalone signal. SEC insider filing
• Negative Sentiment: Several law firms publicized a securities-fraud class action against Hims & Hers and certain executives. The lawsuit follows the FTC’s federal complaint, which allegedly concerns deceptive business practices and privacy-related misstatements or omissions. Investors who purchased shares between August 4, 2025, and July 29, 2026, have until November 2, 2026, to seek lead-plaintiff status. The allegations have not been proven, but the litigation creates legal costs, reputational risk, and uncertainty around potential financial liability. Hagens Berman class-action announcement

Analyst Ratings Changes

HIMS has been the subject of a number of research reports. TD Cowen increased their target price on shares of Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a research report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a research report on Tuesday, August 11th. Morgan Stanley raised their price objective on shares of Hims & Hers Health from $21.00 to $28.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 11th. Canaccord Genuity Group lifted their price objective on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Finally, Citigroup reduced their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $32.43.

About Hims & Hers Health

Hims & Hers Health, Inc is a direct-to-consumer telehealth company that provides access to personalized healthcare through its online platforms, Hims and Hers. The company connects consumers with licensed healthcare professionals for virtual consultations, treatment plans and prescription medications where appropriate.

Its services address a range of common health and wellness needs, including sexual health, hair loss, skincare, mental health, weight management and primary care. Hims & Hers offers branded and generic treatments, over-the-counter products, supplements and personal-care products, with services designed for both men and women.

The company was founded in 2016, launched the Hims brand in 2017 and introduced the Hers brand in 2018.